A new era for complex mitral regurgitation.

The ENCIRCLE pivotal trial in The Lancet reports that fully percutaneous, transfemoral, transseptal TMVR (SAPIEN M3) achieved durable MR reduction (≈96% ≤1+ at 1 year), low early mortality, and meaningful improvement in symptoms and quality of life for patients unsuitable for surgery or TEER.

A third pathway for mitral disease is emerging—one built on precision access, valve-in-valve durability planning, and advancing patient selection.

Innovation meeting clinical need. 🚀🫀📈